William Drake

4.5k total citations
83 papers, 2.2k citations indexed

About

William Drake is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, William Drake has authored 83 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Endocrinology, Diabetes and Metabolism, 16 papers in Surgery and 15 papers in Pulmonary and Respiratory Medicine. Recurrent topics in William Drake's work include Pituitary Gland Disorders and Treatments (35 papers), Growth Hormone and Insulin-like Growth Factors (34 papers) and Pulmonary Hypertension Research and Treatments (14 papers). William Drake is often cited by papers focused on Pituitary Gland Disorders and Treatments (35 papers), Growth Hormone and Insulin-like Growth Factors (34 papers) and Pulmonary Hypertension Research and Treatments (14 papers). William Drake collaborates with scholars based in United Kingdom, United States and Germany. William Drake's co-authors include John P. Monson, Peter Trainer, Ashley Grossman, G. M. Besser, Stephen M. Shalet, Simon Howell, Cecilia Camacho‐Hübner, D. Coyte, Diana Wood and Andrea Rockall and has published in prestigious journals such as Nature Genetics, Endocrine Reviews and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

William Drake

79 papers receiving 2.2k citations

Peers

Countries citing papers authored by William Drake

Since Specialization

Citations

This map shows the geographic impact of William Drake's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William Drake with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William Drake more than expected).

Fields of papers citing papers by William Drake

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William Drake. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William Drake. The network helps show where William Drake may publish in the future.

Co-authorship network of co-authors of William Drake

This figure shows the co-authorship network connecting the top 25 collaborators of William Drake. A scholar is included among the top collaborators of William Drake based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William Drake. William Drake is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Monitoring patients receiving dopamine agonist therapy for hyperprolactinaemia 2020 ·Annales d Endocrinologie ·Craig E Stiles, Richard P. Steeds, William Drake	6
2	Retrospective Database Analysis of Treatment Patterns Among Patients with Pulmonary Arterial Hypertension 2019 ·Pulmonary Therapy ·Sean Studer, Michael Hüll, (unknown), (unknown), Yuen Tsang, William Drake	13
3	Characterizing Patients Treated With Macitentan For Pulmonary Arterial Hypertension (PAH) In The U.S. Opsumit Users Registry (OPUS) 2018 ·Value in Health ·(unknown), (unknown), (unknown), (unknown), Mona Selej, William Drake	1
4	Medication Adherence and Risk of Hospitalization in Pulmonary Arterial Hypertension (PAH) Patients Treated with Endothelin Receptor Antagonists (ERAS) or Phosphodiesterase Type 5 Inhibitors (PDE5IS) 2017 ·Value in Health ·(unknown), (unknown), (unknown), (unknown), (unknown), William Drake	1
5	The Burden of Illness of Mycosis Fungoides Cutaneous T-Cell Lymphoma: A Retrospective Cohort Study of a Commercially Insured Population in the U.S 2016 ·Value in Health ·T. Gu, (unknown), (unknown), William Drake	2
6	The Role of Radiotherapy in Acromegaly 2015 ·Neuroendocrinology ·Mark J. Hannon, Ariel L. Barkan, William Drake	23
7	Effective Combination Treatment with Cabergoline and Low-Dose Pegvisomant in Active Acromegaly: A Prospective Clinical Trial 2012 ·The Journal of Clinical Endocrinology & Metabolism ·Claire Higham, A. B. Atkinson, Simon Aylwin, Martin Bidlingmaier, William Drake, A A M Lewis, Niamh Martin, (unknown), John Newell‐Price, Peter Trainer	76
8	Hutchison's clinical methods : an integrated approach to clinical practice 2012 ·Elsevier eBooks ·Michael Glynn, William Drake, R. Hutchison	19
9	Low Immunohistochemical Expression of MGMT in ACTH Secreting Pituitary Tumors of Patients with Nelson Syndrome 2010 ·Endocrine Pathology ·Fateme Salehi, Bernd W. Scheithauer, (unknown), William Drake, Luis V. Syro, Branavan Manoranjan, (unknown), Éva Horváth, Kálmán Kovács	12
10	Successful use of weekly pegvisomant administration in patients with acromegaly 2009 ·European Journal of Endocrinology ·Claire Higham, (unknown), Martin Bidlingmaier, William Drake, Peter Trainer	30
11	d3‐GHR genotype does not explain heterogeneity in GH responsiveness in hypopituitary adults 2009 ·Clinical Endocrinology ·(unknown), David Walker, (unknown), (unknown), Louise Metherell, Scott Akker, John P. Monson, Adrian Clark, William Drake	16
12	Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials 2008 ·European Journal of Endocrinology ·Camilo Jiménez, Pia Burman, Roger Abs, David R. Clemmons, William Drake, (unknown), Michael Messig, Michael O. Thorner, Peter Trainer, Robert F. Gagel	46
13	Glucose Homeostasis and Safety in Patients with Acromegaly Converted from Long-Acting Octreotide to Pegvisomant 2005 ·The Journal of Clinical Endocrinology & Metabolism ·Ariel L. Barkan, Pia Burman, David R. Clemmons, William Drake, Robert F. Gagel, Philip E. Harris, Peter Trainer, Aart Jan van der Lely, Mary Lee Vance	138
14	Clinical Use of Pegvisomant for the Treatment of Acromegaly 2003 ·PubMed ·William Drake, Peter Trainer	6
15	The Effect of Cessation of Growth Hormone (GH) Therapy on Bone Mineral Accretion in GH-Deficient Adolescents at the Completion of Linear Growth 2003 ·The Journal of Clinical Endocrinology & Metabolism ·William Drake, Paul Carroll, (unknown), Kelly Metcalfe, Cecilia Camacho‐Hübner, N. Shaw, David B. Dunger, Tim Cheetham, M O Savage, John P. Monson	80
16	The effect of pegvisomant‐induced serum IGF‐I normalization on serum leptin levels in patients with acromegaly 2003 ·Clinical Endocrinology ·Craig Parkinson, Andrew Whatmore, Allen P. Yates, William Drake, Georg Brabant, Peter Clayton, Peter Trainer	22
17	Experience with pegvisomant in the treatment of acromegaly 2001 ·Growth Hormone & IGF Research ·William Drake	4
18	Dose-related effects of growth hormone on IGF-I and IGF-binding protein-3 levels in non-islet cell tumour hypoglycaemia 1998 ·European Journal of Endocrinology ·William Drake, (unknown), (unknown), M Yateman, (unknown), C Camacho-Hübner, JP Monson	26
19	Intracardiac metastases from neuroendocrine tumours 1997 ·Clinical Endocrinology ·William Drake, P Jenkins, Rachel R. Phillips, Donna Lowe, Ashley Grossman, G. M. Besser, John Wass	17
20	A technique for displaying the entire nerve branching pattern of a whole muscle: Results in 10 canine posterior cricoarytenoid muscles 1993 ·The Laryngoscope ·William Drake, (unknown), Michael A. Rothschild, Bei‐Lian Wu, Hugh F. Biller, Ira Sanders	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact